Clinical Trial Update: Phase 4 Study: Long-term Safety and Efficacy of NT-501 in MacTel Type 2, Including Sham Procedure Participants [Phase 4]

View source ↗

Summary

Phase 4 clinical trial update for NT-501 assessing long-term safety and efficacy in Macular Telangiectasia Type 2, including sham procedure participants; curren…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Macular Telangiectasia Type

Drugs mentioned

• NT-501

Snippet

Sponsor: Neurotech Pharmaceuticals | Conditions: Macular Telangiectasia Type 2 (MacTel) | Phase 4 | Status: RECRUITING